Outpatient use of Azithromycin increases risk of CVD and non CVD death: JAMA

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-06-19 09:45 GMT | Update On 2020-06-19 10:00 GMT

USA: Outpatient azithromycin use increases the risk of cardiovascular (CV) death and noncardiovascular death, according to a recent study in the JAMA Network Open.

Azithromycin is one of the most commonly prescribed antibiotics in the US. A safety concern was raised following a study that associated azithromycin use with sudden cardiac death. Prompted by the concern over its safety issues, Jonathan G. Zaroff, Division of Research, Kaiser Permanente Northern California, Oakland, and colleagues conducted the study to estimate the relative and absolute risks of cardiovascular and sudden cardiac death after an outpatient azithromycin prescription compared with amoxicillin.

Supported by the drugmaker, researchers retrospectively compared outcomes in some 3 million patients prescribed either azithromycin or amoxicillin -- an antibiotic not known to increase cardiovascular events. Data were analyzed from December 1, 2016, to March 30, 2020. The primary outcomes were cardiovascular death and sudden cardiac death.

The study included 7 824 681 antibiotic exposures, including 1 736 976 azithromycin exposures (22.2%) and 6 087 705 amoxicillin exposures (77.8%), among 2 929 008 unique individuals (mean [SD] age, 50.7 [12.3] years; 1 810 127 [61.8%] women).

Key findings of the study include:

Azithromycin was associated with a significantly increased hazard of cardiovascular death (hazard ratio [HR], 1.82) but not sudden cardiac death (HR, 1.59) within 5 days of exposure.
No increases in risk were found 6 to 10 days after exposure.
Similar results were observed in patients within the top decile of cardiovascular risk (HR, 1.71).
Azithromycin was also associated with an increased risk of noncardiovascular death (HR, 2.17) and all-cause mortality (HR, 2.00) within 5 days of exposure.

"There was an approximately 2-fold increased risk of cardiovascular death and noncardiovascular death after outpatient azithromycin use compared with the use of amoxicillin within a 5-day window after dispensing," wrote the authors. "Although these analyses cannot establish causality, prescribers should be aware of this potential association," they concluded.

The study, "Association of Azithromycin Use With Cardiovascular Mortality," is published in the JAMA Network Open.

DOI: 10.1001/jamanetworkopen.2020.8199

Key Points Español 中文 (Chinese)

Article Source : JAMA Network Open

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Outpatient use of Azithromycin increases risk of CVD and non CVD death: JAMA

Similar News

Uterine Fibroids Linked to 50 Percent Higher Risk of Atrial Fibrillation in Young Women: Study

Diabetes Increases Risk of Oral and Maxillofacial Diseases: Study

Valgus Knee Brace Eases Walking Pain in Osteoarthritis Patients: Trial Shows

Betel Quid Use Linked to Higher Risk of COPD Deaths, Study Finds

New Malaria Vaccine Candidate Blocks Parasite Transmission, Study Shows

Tirzepatide- A novel therapeutic against metabolic dysfunction-associated steatotic liver disease, reports research

Insulin degludec 3-times weekly Less Effective Than insulin glargine once-daily in Short-Term Glycemic Control: Study

Scientists find yoga less effective than traditional exercise in improving vascular and heart function: Study